Biopharma Business

Tag "diabetes therapy"

Merck and Pfizer’s diabetes therapy under US, EU review

Regulators on both sides of the Atlantic are reviewing three new submissions for medicines containing ertugliflozin, an investigational SGLT2 inhibitor being developed by Merck and Pfizer to help improve glycaemic

Read Full Article

Upcoming Events


The Magazine

New Subscriber

Subscribe Here